Prostate Cancer

Text Size A A

E-Mail to a Friend

secret  Click to Play Audio

Participate in a Study

Patients who participate in clinical studies have the first chance to benefit from treatments that have shown promise in earlier research. They also make an important contribution to medical science by helping doctors learn more about prostate cancer and by helping the men who will face similar decisions about how to deal with their disease in the future. Although clinical studies may pose some risks, clinicians take careful steps to protect the people who participate.

In particular, men who have advanced prostate cancer or whose cancer has returned despite treatment may want to consider enrolling in a clinical study in order to receive a promising treatment that is only available through a study.

Our doctors and researchers are evaluating a number of promising new treatments, including prostate cancer vaccines, several new types of hormone therapy and new chemotherapy regimens, including chemotherapy plus hormone therapy and chemotherapy plus immunotherapy.

Grants Awarded to SCCA

SCCA received a Specialized Program of Research Excellence (SPORE) grant for our prostate cancer science expertise and a Department of Defense (DOD) Clinical Trials Consortium grant for our clinical studies expertise. The SPORE grant was awarded to only 11 institutions around the country and the DOD grant to only 13 institutions. SCCA is one of only five institutions with both of these important research grants currently funded, a testament to our expertise and dedication to treating and curing prostate cancer.

SCORE—Study of Cognition, Oncology and Report of Emotions

Starting hormone therapy for prostate cancer? About to begin androgen-deprivation therapy? We need you! The University of Washington is currently enrolling patients who are ready to begin hormone therapy, also known as androgen-deprivation therapy, in a study on mood, information processing and quality of life.

For more information or to enroll, call (206) 277-1058 (Tom Erickson), (206) 948-8880 or (866) 577-1913. Or email us at (Note that the confidentiality of e-mail cannot be guaranteed.) Learn more about the study.